Changing trends in gestational trophoblastic disease

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 51, Issue 10, 2006, Pages 777-784

  Smith, Harriet O ^a   Wiggins, Charles ^b   Verschraegen, Claire F ^b   Cole, Laurence W ^b   Greene, Heather M ^b   Muller, Carolyn Y ^b   Qualls, Clifford R ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b NONE

Author keywords

Age adjusted incidence rates; American Indians; Blacks; Choriocarcinoma; Gestational trophoblastic disease; Hispanics

Indexed keywords

ADULT; AFRICAN AMERICAN; AMERICAN INDIAN; CALCULATION; CANCER INCIDENCE; CANCER REGISTRY; CANCER SURVIVAL; CHORIOCARCINOMA; CONFERENCE PAPER; DATA ANALYSIS; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; HEALTH SURVEY; HIGH RISK POPULATION; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; SURVIVAL RATE; TREND STUDY; TROPHOBLASTIC TUMOR; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; DISEASE-FREE SURVIVAL; ETHNIC GROUPS; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HEALTH TRANSITION; HUMANS; INCIDENCE; MATERNAL HEALTH SERVICES; MATERNAL MORTALITY; MIDDLE AGED; NEW MEXICO; POPULATION SURVEILLANCE; PREGNANCY; REGISTRIES; SEER PROGRAM; SURVIVAL ANALYSIS; UTERINE NEOPLASMS;

EID: 33750221864     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. American College of Obstetricians and Gynecologists: Diagnosis and treatment of gestational trophoblastic disease. Obstet Gynecol 2004;103:1365-1377
2. Benedet JL, Bender H, Jones H 3rd, et al: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers: FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-262
3. Kohorn EI: Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia; A progress report. J Reprod Med 2002;47:445-450
4. Kohorn EI: The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assessment. Int J Gynecol Cancer 2001;11:73-77
5. Shanmugaratnam K, Muir CS, Tow SH, et al: Rates per 100,000 births and incidence of choriocarcinoma and malignant mole in Singapore Chinese and Malays: Comparison with Connecticut, Norway and Sweden. Int J Cancer 1971; 8:165-175
6. Smith HO: Gestational trophoblastic disease epidemiology and trends. Clin Obstet Gynecol 2003;46:541-556
7. Bracken MB, Brinton LA, Hayashi K: Epidemiology of hydatidiform mole and choriocarcinoma. Epidemiol Rev 1984;6: 52-75
8. Palmer JR: Advances in the epidemiology of gestational trophoblastic disease. J Reprod Med 1994;39:155-162
9. Kim SJ, Bae SN, Kim JH, et al: Epidemiology and time trends of gestational trophoblastic disease in Korea. Int J Gynaecol Obstet (suppl 1) 1998;60:S33-S38
10. Hando T, Ohno M, Kurose T: Recent aspects of gestational trophoblastic disease in Japan. Int J Gynaecol Obstet (suppl 1)1998;60:S71-S76
11. Chattopadhyay SK, Sengupta BS, al-Ghreimil M, et al: Epidemiologic study of gestational trophoblastic diseases in Saudi Arabia. Surg Gynecol Obstet 1988;167:393-398
12. Kim SJ, Lee C, Kwon SY, et al: Studying changes in the incidence, diagnosis and management of GTD: The South Korean model. J Reprod Med 2004;49:643-654
13. Smith HO, Hilgers RD, Bedrick EJ, et al: Ethnic differences at risk for gestational trophoblastic disease in New Mexico: A 25-year population-based study. Am J Obstet Gynecol 2003; 188:357-366
14. Smith HO, Quails CR, Hilgers RD, et al: Gestational trophoblastic neoplasia in American Indians. J Reprod Med 2004;49:535-544
15. Smith HO, Quails CR, Prairie BA, et al: Trends in gestational choriocarcinoma: A 27-year perspective. Obstet Gynecol 2003;102:978-987
16. Brinton LA, Bracken MB, Connelly RR: Choriocarcinoma incidence in the United States. Am J Epidemiol 1986;123:1094-1100
17. Fritz A, Percy C, Jack A, et al: International Classification of Diseases for Oncology (ICD-0). Third edition. Geneva, World Health Organization, 2000
18. Weller EA, Ryan LM; Testing for trend with count data. Biometrics 1998;54:762-773
19. Smith P: Comparison between registries: Age-standardized rates. In Cancer Incidence in Five Continents. Sixth volume. Edited by DM Parkin, CS Muir, SL Whelan, et al. Lyon, IARC, 1992
20. Breslow NE, Day NE: Statistical Methods in Cancer Research. Second volume. The Design and Analysis of Cohort Studies. London, IARC Scientific Publications, Lyon, Oxford University Press, 1987
21. Cunningham J, Ries L, Hankey B, et al: The SEER Program Code Manual. Revised edition. Bethesda, National Institutes of Health, 1999
22. SEER Stat 6.1.4: SEER Cancer Incidence Public-Use Database, 1973-2002. Bethesda, US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, Cancer Statistics Branch, 2005
23. Jensen OM, Parkin DM, MacLennan R, et al: Cancer Registration Principles and Methods. Ninety-fifth volume. London, Lyon, Oxford University Press, 1991
24. Fay MP, Feuer EJ: Confidence intervals for directly standardized rates: A method based on the gamma distribution. Stat Med 1997;16:791-801
25. Fay MP: Approximate confidence intervals for rate ratios from directly standardized rates with sparse data. Commun Stat 1999;28:2141-2160
26. Kleinbaum D, Kupper L, Muller K: Applied Regression Analysis and Other Multivariate Methods. North Sciutate, Massachusetts, Duxbury Press, 1988
27. Brown CC: The statistical comparison of relative survival rates. Biometrics 1983;39:941-948
28. Drake RD, Rao GG, McIntire DD, et al: Gestational trophoblastic disease among Hispanic women: A 21-year hospital-based study. Gynecol Oncol 2006 (in press)
29. Bagshawe KD, Dent J, Webb J: Hydatidiform mole in England and Wales 1973-83. Lancet 1986;2:673-677
30. Soper JT: Identification and management of high-risk gestational trophoblastic disease. Semin Oncol 1995;22:172-184
31. Massad LS, Abu-Rustum NR, Lee SS, et al: Poor compliance with postmolar surveillance and treatment protocols by indigent women. Obstet Gynecol 2000;96:940-944